The content on this site is intended for healthcare professionals only
Dr Timothy Yap speaks to ecancer about the PETRA trial that he presented at the AACR 2022 meeting. The trial was a first in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1/2, PALB2 or RAD51C/D mutations.
He reports that the results showed that AZD5305 successfully improved safety and showed promising clinical activity.
Dr Yap believes that this is proof of concept in the clinic for this innovative strategy and that expansion trials are in the works.
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
Understanding the use of PARPi combinations to treat patients with mCRPC
ESMO 2024: Optimising the personalisation of prostate cancer treatment
ARV-766 well tolerated and shows promising clinical activity in metastatic castration-resistant prostate cancer
OncoAlert round up July 28th to August 3rd, 2023
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
Hypofractionated high dose intensity modulated radiotherapy non-inferior for prostate cancer
Loco-regional management after neoadjuvant chemotherapy
